Start biologic DMARDs early in juvenile idiopathic arthritis: study

Disease activity is lower after a year with aggressive combined therapy approach, say researchers

Early aggressive use of biological disease-modifying antirheumatic drugs (bDMARDs) is more effective for newly diagnosed polyarticular course juvenile idiopathic arthritis (JIA) than a delayed approach, researchers say.